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Summary  
Background 
Deep brain stimulation (DBS) has been proposed as a treatment option for severe Tourette 
syndrome (TS), based on open-label series and blinded data from a small number of 
individuals.  This study aimed to further evaluate the safety and efficacy of bilateral globus 
pallidus internus (GPi) DBS in this patient group. 
 
Methods 
In this randomized, double-blind, crossover trial, eligible patients (severe medically refractory 
TS, aged ≥20 years old) were recruited from 2 tertiary movement disorders clinics in the UK, 
received GPi DBS surgery, then were randomly assigned (1:1) to either “stimulation-ON first” 
or “stimulation-OFF first” for a three-month period followed by a switch to the opposite 
condition for a further three-month period. Neither patients nor rating clinicians were aware 
of their computer-generated treatment allocation. An unmasked clinician was responsible for 
programing the stimulation. The primary endpoint was the difference in Yale Global Tic 
Severity Scale (YGTSS) total score between the two blinded conditions using repeated 
measures ANOVA. After completing the double-blind crossover period, patients continued to 
have open-label stimulation adjustments and objective assessments of tic severity until 
database lock one month after the final patient’s final trial related visit. The trial was 
registered with ClinicalTrials.gov, number NCT01647269. 
 
Findings  
Data were collected between August 2011 and December 2014. Of the 15 patients enrolled, 
13 patients completed the double-blinded period. The mean YGTSS total score was 87·9 
(SD 9·2) at baseline, 80·7 (SD 12·0) with DBS OFF and 68·3 (SD 18·6) with DBS ON. 
Repeated measures ANOVA revealed a significant interaction between timepoint and 
YGTSS total scores (Wilks Lamba =0·45, F(2,11)= 6·6, p=0·013). Pairwise comparisons in 
YGTSS total scores after Bonferroni correction were significantly lower at the end of the ON 
 
 
compared to the OFF blinded stimulation condition with a mean improvement of 12·4 points 
(95% CI 0·10- 24·7, p=0·048) equivalent to 15·3%. Between trial commencement and 
database lock, 3 serious adverse events were observed; 2 DBS hardware infections, (2 & 7 
weeks post-operatively) & 1 episode of DBS induced hypomania, during the blinded ON 
stimulation phase, all of which resolved with treatment. 
 
Interpretation 
Globus pallidus stimulation led to a significant improvement in tics during the ON compared 
to the OFF blinded condition, with an overall acceptable safety profile.  Future research 
should concentrate on identifying the most effective deep brain stimulation target to control 
both tics and associated comorbidities, and further clarify those factors predicting individual 
patient responses to this treatment option. 
 
Funding 
This was an investigator-initiated study with funding provided through UK National Health 
Service (NHS) Individual Funding Requests. 
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Introduction  
The clinical hallmark of Tourette syndrome (TS) is the presence of multiple motor and vocal 
tics, often preceded by premonitory sensations or urges and frequently complicated by 
neurobehavioral comorbidities, including attention deficit hyperactivity disorder (ADHD), 
obsessive compulsive disorder (OCD), impulse control disorder, self-injurious behaviour 
(SIB), as well as personality and mood disorders.1–3 
 
The majority of TS patients experience a pre-pubertal increase in tic severity, followed by a 
remission towards late adolescence or early adulthood. Nevertheless, a significant number 
of patients may continue to experience disabling symptoms in adulthood and require lifelong 
treatment.4 Behavioural therapies, alpha-2 adrenergic agonists, antipsychotic agents, 
anticonvulsant drugs, benzodiazepines, and botulinum toxin injections may all offer some 
symptomatic relief.2,3 Nevertheless in a proportion of patients, these approaches are 
insufficiently effective or accompanied by intolerable side effects and among this group there 
remain a number of severely affected patients for whom surgical approaches such as deep 
brain stimulation (DBS), may present an alternative treatment option.5 
 
The first report of DBS for the treatment of refractory TS was published in 1999 by 
Vandewalle et al, targeting the same thalamic nuclei, (i.e. centromedian /parafascicular 
complex -CM/Pf, and ventral oral internus nuclei) which were subject to stereotactic ablation 
by Hassler & Dieckmann in the 1970s.6,7 Since then, various areas of the brain have been 
targeted by DBS including the centromedian–parafascicular complex of the thalamus, the 
subthalamic nucleus, nucleus accumbens and anterior limb of the internal capsule, and the 
globus pallidus internus and externus, providing variable but generally positive results.5 
 
Supportive evidence is however mostly based on case reports or in small case series 
typically in non-blinded studies involving limited number of patients. Open-label beneficial 
effects of DBS targeting the CM/Pf thalamic nuclei have been partially supported by two 
small randomized trials including 5 and 6 patients respectively, but have raised significant 
issues about the safety and tolerability of this target.8–10  
 
There is extensive evidence for the efficacy of GPi DBS in other hyperkinetic movement 
disorders, L-dopa induced dyskinesia, or various forms of dystonia that support the use of 
GPi as an attractive alternative target for DBS in TS.11,12 In a series of 3 patients comparing 
bilateral thalamic and bilateral anteromedial GPi stimulation, combined and sham 
 
 
stimulation, Welter and co-workers demonstrated an advantage of  anteromedial GPi DBS 
that was sustained for 20–60 months of follow-up.13 Further open-label studies have also 
suggested that GPi DBS might be a promising therapeutic alternative for severe medically 
refractory TS with an acceptable safety profile.14–16 
 
However, there remain a number of unanswered questions regarding DBS for TS including; 
the objective demonstration of its efficacy on different aspects of TS, the factors that predict 
individual patient responsiveness, as well as the methods for deriving optimal stimulation 
parameters, and the precise optimal choice of brain target. Thus, DBS for TS is still 
considered as an experimental approach. Well-designed randomized double-blind trials, 
involving a multi-disciplinary team approach are needed to help address these questions. In 
the current trial, we assessed the clinical efficacy and safety of bilateral GPi DBS in a cohort 
of 15 patients with treatment refractory, severe TS, using a randomized, double-blind, 
crossover design followed by ongoing open-label evaluation.   
 
Methods 
Patients 
Patients were eligible for inclusion if they were adults with stable Tourette’s syndrome; had 
chronic and severe tic disorder with severe functional impairment in Yale Global Tic Severity 
Scale (YGTSS) of at least 35/55 for at least 12 months prior to surgery; had failed 
conventional medical treatment at therapeutic doses of three classes of medication; 
behavioural intervention had been considered inappropriate or had been unsuccessful; had 
optimised treatment of co-morbid conditions for at least 6 months; and were compliant with 
any psychosocial interventions/ with surgical treatment plans.  The exclusion criteria were: 
tic disorder attributable to another condition; presence of other medical or psychiatric 
disorders that might increase the risk of the procedure; psychosocial factors which might 
impede operative/post-operative care and research participation; coagulation problems; 
other disease compromising life expectancy; still likely to benefit from psychological 
intervention; pregnancy; age < 20 years.  
 
Study design 
The study was sponsored by University College London, and was conducted in two 
academic centres in the UK (UCL Institute of Neurology, London and Salford Royal NHS 
Foundation Trust, Manchester). The study was designed to compare tic severity during 3 
months “ON-stimulation” with 3 months “OFF-stimulation” in a randomized double-blind, 
sham stimulation controlled, crossover manner. The trial conformed to the Declaration of 
Helsinki, Good Clinical Practice guidelines, and was approved by the ethics committees at 
participating centres. All patients provided written informed consent before enrolment. The 
trial was registered with ClinicalTrials.gov, number NCT01647269. 
 
Procedures 
Each patient was screened for eligibility at a multidisciplinary evaluation, including 
assessment by at least one neurologist, functional neurosurgeon, neuropsychiatrist and 
neuropsychologist (figure 1). All patients underwent a baseline assessment, followed four 
weeks later by stereotactic implantation of bilateral DBS electrodes (model 3387 or 3389, 
Medtronic, Minneapolis, MN, USA) into the GPi. In London, implantation of bilateral DBS 
electrodes was guided by individual targeting on stereotactic proton density MRI, visualizing 
the individual pallidal target. A Leksell stereotactic frame was used, without microelectrode 
recording and with immediate postoperative stereotactic MRI to document electrode location 
in relation to the patient’s individual anatomy. All patients were operated under general 
anaesthesia. Full details of this neurosurgical procedure have been published previously.17,18 
In Salford, target verification was confirmed using MR imaging of bilateral plastic stylettes 
prior to the insertion of the final DBS electrodes that followed the same trajectory.19 All 
patients received Activa® PC, (Medtronic, Minneapolis, MN, USA) implantable pulse 
generators (IPGs). 
 
 
All participants were scheduled for a first post-operative assessment six weeks following 
DBS implantation. Following this assessment, patients were screened for the effects of 
stimulation. Stimulation parameters were adjusted during a one-week un-blinded period. The 
optimal settings were determined by using the most effective parameters on tics with the 
lowest energy, without causing side effects. Patients were then randomly assigned in pairs 
to “stimulation-ON first” or “stimulation-OFF first”, for the subsequent three months, following 
which they would switch to the opposite condition. The patients were routinely contacted at 
least once monthly and intermediate blinded adjustments/ pseudo-adjustments were 
performed by a non-blinded member of the trial team, as instructed by the blinded clinician 
according to tic control/reported side effects. Detailed assessments were scheduled at the 
end of each of the three-month blinded periods (figure 1).  
 
At the end of the blinded trial period patients were given the option of having their stimulators 
permanently switched ON. Patients were invited to routine follow-up and assessed in an 
open-label fashion at least every 6 months until database lock, with further adjustments to 
their stimulation parameters made as necessary.  
 
Formal assessments were performed at each visit as per trial protocol by a clinician blinded 
to stimulation status, and included the completion of the following scales: Yale Global Tic 
Severity Scale (YGTSS), Yale-Brown Obsessive Compulsive scale (Y-BOCS), Modified 
Rush Video Rating Scale (MRVRS), Diagnostic Confidence Index (DCI), MOVES scale, and 
Tourette Quality of Life Scale (GTS-QOL). They also completed the Beck Depression 
inventory (BDI), the State-Trait Anxiety Index (STAI), the Neuropsychiatric Inventory (NPI) as 
well as a battery of neuropsychological tests; the California Verbal Learning test (CVLT), 
Recognition memory for faces (RMF), Verbal fluency, Trail Making test B (TMT-B), Stroop 
interference test, Letter Cancellation test, Paced Auditory Serial Addition test (PASAT), Corsi 
blocks. Adverse events were systematically recorded throughout the trial.  
 
Randomization and masking  
Participants were randomly assigned to either “stimulation-OFF first” during which they 
received no stimulation, or “stimulation-ON first”. Computer-generated pairwise 
randomization was performed according to order of enrolment so that comparable numbers 
of patients were recruited to receive each condition first. The randomization sequence was 
generated by the chief investigator and only revealed to the unblinded clinician responsible 
for the programming of the stimulation. The patients and the clinicians directly involved in the 
scoring were not aware of the condition of stimulation. The unblinded clinician responsible 
for the DBS programming spent the same time adjusting the stimulator of the patients at the 
start of the ON or OFF-stimulation periods. Adjustment/ pseudo-adjustments were performed 
in an identical manner during both blinded phases based on instruction from the blinded 
clinician that response to treatment was sub-optimal and using increments of 0·1-0·2V. The 
electrical parameters were selected to avoid side effects and amplitudes gradually increased 
at the start of the ON period to avoid any sensation of stimulation being perceived by the 
patients.  
 
Outcome measures 
The pre-specified primary end point was the difference in tics between the two blinded 
stimulation conditions including all individuals that completed both blinded phases, as 
assessed using the YGTSS total score. Pre-specified secondary outcomes were change in 
the following validated scales: Y-BOCS, GTS-QOL, BDI, NPI, STAI and the battery of 
neuropsychological tests in OFF- versus ON-stimulation conditions. Additional post-hoc 
analyses were performed to evaluate the impact of surgery on tic severity prior to 
stimulation; to compare changes in MRVRS, MOVES scale, motor and vocal tic and 
impairment subscores of the YGTSS and to assess the change between baseline and open-
label assessments among all patients utilising the latest available open-label follow-up.  
 
 
 
Statistical Analysis 
The sample size of this study was based on practical considerations, given that available 
data with regards to efficacy/variance of pallidal DBS for Tourette’s syndrome were 
insufficient to enable a formal power calculation. Raw scores for the primary endpoint for 
each recruited patient are presented to maximise transparency of the range of outcomes. 
The primary and secondary endpoints were compared at baseline, OFF– and ON-stimulation 
using repeated measures ANOVA. Pairwise comparisons (with Bonferroni correction) were 
performed for those endpoints with significant main effects of timepoint. The effect of 
randomisation sequence on the difference between blinded ON and OFF YGTSS scores 
was compared using an unpaired t test. Post hoc comparisons of baseline against open 
label scores were performed using paired t tests. All data were analysed using Statistical 
Package for the Social Sciences version 21·0 software (SPSS, Chicago, IL, USA).  
 
Funding 
This was an investigator-initiated study with no commercial sponsorship or funding. Funding 
for DBS procedures was sought from each individual’s National Health Service (NHS) 
primary care trust using individual funding requests in advance of the surgery. The NHS had 
no role in the design, data collection, analysis or interpretation of the trial or the writing of the 
report. All authors had full access to all of the data. Dr Foltynie had responsibility for the final 
decision to submit the report for publication. 
 
Results 
Study population 
Of 18 patients assessed for eligibility, 15 patients (11 male, mean age 34·7) were enrolled 
(figure 2). Table 1 summarizes their clinical characteristics. 
  
DBS Surgery 
All DBS procedures were performed between August 2011 and April 2014. Thirteen patients 
had bilateral electrodes in the anteromedial GPi. Two patients with concurrent 
dystonia/dystonic tics had bilateral electrodes placed slightly more posteriorly towards the 
posteroventral GPi aiming to maximise improvement in their dystonia while still adhering to 
the trial protocol, and given the absence of evidence regarding which subregion of the GPi 
may be most effective for tic suppression (figure 3). 
 
Protocol withdrawals/deviations 
Two patients withdrew from the ON/OFF blinded crossover phase of the trial, one before and 
one soon after randomization, because of their concerns of the additional delay in potential 
therapeutic effects associated with the crossover period. In accordance with their ethics 
committee approved trial consent, both immediately received open-label continuous 
stimulation. Thirteen patients completed the randomization period; 6 randomly assigned to 
“stimulation-ON first” and 7 to “stimulation-OFF first” (figure 2). Three of these had protocol 
deviations, including 1 patient withdrawing from the blinded phase of the trial 1 month early 
due to increased anxiety associated with the blinding, and 2 patients having incomplete 
assessments at trial visits due to patient fatigue. Two patients had medication changes 
during the 6 months of the blinded protocol (1 patient had initiation of diazepam 5mg and 
fluoxetine 20mg halfway during stimulation-ON period and continued during stimulation-OFF 
period due to exacerbation of anxiety, and a second patient discontinued haloperidol during 
stimulation-OFF period due to intolerance of pre-existing sedative side effects).  
 
Efficacy of stimulation – Primary outcome YGTSS 
Table 2 presents the individual and mean YGTSS total scores for all 15 patients. Repeated 
measures ANOVA revealed a significant interaction between timepoint and YGTSS total 
scores (Wilks Lamba =0·45, F(2,11)= 6·6, p=0·013). Pairwise comparisons of YGTSS total 
scores after Bonferroni correction confirmed significantly lower scores at the end of 
stimulation-ON blinded period in comparison to the end of the stimulation-OFF blinded 
 
 
period (n=13) with a mean improvement of 12·4 points (95% CI 0·1-24·7, p=0·048), 
equivalent to 15·3%.  
 
Additional pair-wise comparisons between baseline and OFF stimulation showed an 
improvement of 7·2 points (95% CI -0·2 – 14·7) of marginal significance (p=0·059 after 
Bonferroni correction), while between baseline and ON stimulation confirmed an 
improvement of 19·6 points (95% CI 5·0-34·3, p=0·009 after Bonferroni correction). There 
was no between group difference in the primary outcome according to the sequence of the 
randomization (t= 0.023, p=0.98). 
 
Efficacy of stimulation- Pre-specified Secondary Outcomes 
There was a significant effect of timepoint on GTS-QOL and CVLT immediate recall  scores 
(Table 3) but no significant differences comparing blinded ON vs OFF stimulation scores 
after Bonferroni correction  (GTS-QOL (p=1.0), CVLT immediate recall (p=0.07)). There 
were no other significant changes in other secondary outcomes comparing baseline, blinded 
ON and OFF stimulation timepoints. 
 
Post hoc analyses 
Seven patients had an improvement in tic severity based on the 6 week post-operative, pre-
stimulation assessment possibly indicating a residual microlesion effect of the surgery (Table 
2.) In the blinded period comparison of the sub-items of the YGTSS, there was a significant 
effect of timepoint for the mean motor tic, vocal tic and impairment sub-scores, but only the 
motor subscore remained significant in the ON compared to the OFF condition after 
Bonferroni correction (p=0.039). There was also a significant effect of timepoint in the mean 
MRVRS observed and unobserved scores, together with a significant improvement in the 
ON compared to OFF condition in the mean observed MRVRS score (p=0.031)(table 3). 
Beyond the blinded crossover trial period, all 13 patients opted to have their stimulators 
permanently switched-ON and (alongside the 2 patients who withdrew from the blinded 
phase of the trial) were followed on an open-label basis for a mean of 16·7 months (range 8-
36) post-operatively. Open-label YGTSS total scores (n=15) at latest follow up were reduced 
by 40·1% compared with baseline (mean score 51·5 vs 87·9, p<0·0001)  (table 2). At this 
timepoint, all secondary outcome measures were also significantly improved except Y-BOCS 
and STAI (table 3).  
 
Optimising stimulation parameters 
During the blinded period, electrical stimulation was delivered as single monopolar 
stimulation in 9 patients and as double monopolar stimulation in the remaining 4. The 
stimulation amplitudes were deliberately constrained to avoid unblinding ON/ OFF status 
during this period. During the subsequent open-label period, stimulation was further adjusted 
to achieve maximal symptom control, including further titrations of voltage, pulse-width and 
frequency, the addition of contacts in 3 patients, and complete change of active contacts in 4 
patients. For DBS parameters- See Supplementary material. 
 
Adverse events 
Surgery was well tolerated and all patients were ambulatory within 24h.  Adverse events 
were recorded until database lock (mean period of 16·7 months (range 8-36). Three serious 
adverse events (20%) were reported of which 2 were surgery related and 1 was stimulation 
related. Patients 3 and 7 developed infection of the DBS hardware which necessitated the 
removal of leads, extension cables and IPG and administration of antibiotics. Both patients 
opted to re-enter the trial and were re-implanted 22 months and 6 months post initial 
operation and completed the trial protocol as above. One patient experienced deterioration 
of tics and hypomanic behaviour during the ON-stimulation condition. Hospital admission 
was necessary, following re-screening and alteration of stimulation settings accompanied by 
addition of medications.  Over the whole study period, including the open-label extension of 
 
 
the study, an additional 23 adverse events occurred in 10 patients, 15 of which resolved 
(table 4).  
 
Discussion  
In this double-blind, crossover trial of 15 patients with severe medically refractory TS, globus 
pallidus stimulation led to a significant improvement in tics during the ON compared to the 
OFF blinded condition, with an overall acceptable safety profile. There was a wide range of 
improvements observed during the rigorous double-blind evaluation with greater consistency 
following the initiation of open-label stimulation adjustment. To our knowledge, this is the 
largest double-blind trial of DBS in TS patients published to date, although we are aware that 
other teams are also evaluating this potential target in this population.  
 
The modest improvement we observed in the mean YGTSS and video-based tic counts 
during the blinded phase of the trial, was not reflected in a significant improvement in mean 
quality of life (GTS-QOL) scores or any of the co-morbid psychiatric conditions assessed. 
However, long-term open-label assessment of the patients revealed further mean 
improvement in tics (40·1%) compared with pre-operative baseline, and at latest follow-up, 
continuous GPi stimulation led to a significant mean improvement (38·9%) in quality of life. 
Mood, assessed by BDI also significantly improved, whereas only modest, non-significant 
effects were seen in obsessive compulsive behaviours (Y-BOCS), and anxiety (STAI). 
Greater improvements were seen in motor compared with vocal tics in blinded evaluations, 
although efficacy was similar for tic subtypes in the open-label analysis.  
 
The individual patient responses were presented to maximise transparency; in 6 patients 
there was no clear benefit from stimulation during the blinded phase of the trial (< 10% 
improvement in YGTSS). In the majority of these individuals, a clear improvement was 
obvious in open-label assessment following further changes of the stimulation parameters 
which was consistently contact-specific and reproducible. This is an issue for DBS related 
trials, where adjusting the stimulation while maintaining treatment blinding can compromise 
the identification/use of optimal settings therefore suboptimal stimulation parameters may be 
used out of necessity. In addition, anxiety associated with uncertainty whether stimulation 
was switched ON or OFF, was a particular issue in some patients, which could also at least 
partly explain the more limited effect in patients’ quality life during the blinded period. The 
additional contribution of a transient/persisting post-operative microlesion effect impacting on 
subsequent ON verses OFF stimulation YGTSS assessments in certain patients, cannot be 
excluded. 
 
During open-label optimisation of the stimulation, there were clear improvements in quality of 
life considering the group as a whole. Nevertheless, four patients had less than 20% 
improvement in YGTSS scores compared with baseline without obvious explanation. A 
complex interplay between severity and chronicity of tics on an individual’s learned 
behaviour, comorbid psychiatric symptoms, stimulation related side effects, and also 
patients’ expectations may explain the variability of response to stimulation in these patients.  
 
Most patients responded to average stimulation parameters comparable to those used in 
Parkinson’s disease, with higher levels of stimulation sometimes having a negative impact. 
However, in several patients, and in those showing good response patterns in particular, 
progressive increases in amplitude of stimulation and number of active contacts was 
necessary over time. This raises a concern that tolerance to stimulation may occur and also 
of accelerated battery depletion, both important issues for the long-term care of this relatively 
young population of patients. Of note is that the most dorsal contacts on the electrodes were 
frequently associated with optimal tic responses possibly indicating that stimulation of the 
globus pallidus externus (GPe) might be involved in the mechanism of tic relief.20 
 
 
 
To date, the thalamic DBS target probably remains the best explored in TS.8–10,21–24 
However, despite impressive benefits seen in open-label studies, results have also been 
more modest in small double-blind trials of thalamic DBS for TS. The potential role of 
thalamic DBS for TS with respect to both efficacy and side effects remains a source of 
debate with some centres continuing to report positive open label results24.  
 
In our trial, GPi stimulation was generally well tolerated and stimulation related side effects 
were amenable to stimulation adjustment. Of concern is the infection rate (13%) which is 
higher than expected, and may reflect that higher infection rates are indeed associated with 
DBS in this population, previously estimated to be as high as 18%.25,26 Whether this is due to 
patients’ behaviour or distinct immunological profiles in this population remains unclear.  
 
A limitation of our study remains the relatively small sample size and that in 2 individuals 
electrodes were placed more posteriorly in the GPi as directed by their concurrent dystonic 
features. We cannot conclude whether anteromedial GPi DBS is superior to posteroventral 
GPi DBS for tic suppression based on our results. Moreover, in 2 patients medication 
changes occurred during the blinded period (1 increased, 1 decreased) and thus any 
influence of these changes aside from DBS cannot be excluded. Due to the immediate and 
often obvious effects of DBS adjustment, both blinding and subsequent adherence to trial 
protocol can be easily compromised unless adjustments are limited to minor potentially sub-
therapeutic changes. Even so, delivery of effective stimulation in severely affected patients 
can make maintenance of double-blinding difficult.  These challenges may be overcome in 
future trials by randomising patients to different targets, or comparing different targets within 
patients. However, the common coexistence of significant psychiatric comorbidity, the 
subjective nature of TS related outcome measures and their potential ceiling effects in the 
most severely affected patients, add to the difficulties of trial conduct in TS patients and 
interpreting the results based on individual scales.  
 
In conclusion, our data support the GPi as an attractive alternative for DBS in TS.  The mean 
effect size observed in the blinded period is greater than that seen in double-blind trials of 
medications for TS, and with further follow-up, GPi DBS appears to have major effects on tic 
severity and quality of life of this extremely disabled patient group.  The anteromedial GPi is 
considered as part of the same limbic pathways that are thought to be involved in tic 
generation,27–30 and while it is likely that tics emerge from network based neuronal 
dysfunction, bilateral DBS surgery appears to be well tolerated when targeting the pallidum. 
Additionally the pallidal target can be easily visualized on pre-operative stereotactic MRI 
allowing uniformity of targeting across patients. Future trials comparing the optimal target for 
DBS for TS should include a comparator arm with electrodes in bilateral anteromedial GPi/ 
GPe, and continue to try and identify those factors, which predict individual patient 
responsiveness. 
 
Panel: Research in context 
Evidence before this study 
We searched PubMed up to December 2014 with the terms Tourette’s syndrome, Gilles de 
la Tourette, or Tourette and deep brain stimulation, or DBS for double-blind randomized 
trials. We identified 4 small trials incorporating double-blind randomized methodology. In two 
trials including 5 and 6 patients respectively, the efficacy of thalamic DBS (centromedian–
parafascicular (CM–Pfc) and ventralis oralis complex of the thalamus) was evaluated.9,10 In 
another two trials, the effect of thalamic and anteromedial GPi stimulation was compared in 
1 and 3 patients respectively.13,31 These studies, including very small numbers of patients 
each report a benefit from stimulation, and thus partially support the overall positive 
outcomes presented in open-label studies. However, the literature of DBS for the treatment 
of Tourette syndrome consistently highlights the paucity of the highest level of evidence for 
its use. There remains a need for double-blind, randomized, controlled trials, with a sufficient 
number of patients to address a number of unresolved issues including; the magnitude and 
 
 
consistency of the efficacy of this treatment, its clinical relevance, its effect on comorbid 
conditions, and the overall safety of this approach. The brain target as well as stimulation 
settings that can optimally address the abovementioned issues also remain to be 
determined.  
 
Added value of this study 
Our prospective, randomized trial is the largest double-blind trial of DBS in TS patients to 
date, assessing the safety and efficacy of pallidal DBS. Our results provide high-quality 
evidence that GPi DBS can significantly improve tics and can have major effects in quality of 
life in the long-term, while having an acceptable safety profile. 
 
Implications of all the available evidence 
The outcomes of this study provide further justification for the use of GPi DBS as a treatment 
for patients with severe medically refractory TS, which to date was supported by limited 
evidence. Future trials will likely require cross-centre collaboration to recruit larger numbers 
and evaluate the relative merits of different DBS targets, and identify factors predictive of 
useful response to surgery. 
 
Authors contributions:  
Chief Investigator- Thomas Foltynie supervised all aspects of the trial conduct, was 
responsible for randomisation and masking and provided statistical and methodological 
advice but had no direct role in data collection or data analysis.  
Study design: Ludvic Zrinzo, Eileen Joyce, Marjan Jahanshahi, Thomas Foltynie;  
Data collection: All authors except Thomas Foltynie. 
Analysis of data: Zinovia Kefalopoulou, Ludvic Zrinzo,;  
Statistical analysis: Zinovia Kefalopoulou;  
Interpretation of data- All authors. 
Drafting of the manuscript: Zinovia Kefalopoulou;  
Critical revision of the manuscript: All authors.  
 
Conflict of Interest 
Dr Kefalopoulou is supported by a European Union FP-7 grant (TRANSEURO); Dr Zrinzo, 
Mr Candelario and Mrs Milabo report personal fees from Medtronic Inc; Mr Hyam and Prof 
Hariz report personal fees from Medtronic Inc and St Jude Medical; Prof Limousin reports 
personal fees from Medtronic Inc, St Jude Medical, and Boston Scientific; Dr. Foltynie 
reports personal fees from Medtronic Inc, personal fees from St Jude Medical, grants from 
Michael J Fox Foundation, grants from Cure Parkinson's Trust, grants from Parkinson's UK, 
grants from Brain Research Trust, personal fees from Abbvie Pharmaceuticals.  There is no 
actual or potential conflict of interest in relation to this article. 
 
Acknowledgements 
We are grateful to all the patients who participated in this trial, as well as their referring 
clinicians. This work was undertaken partly at UCL/UCLH and was funded in part by the 
Department of Health NIHR Biomedical Research Centres funding scheme. The Unit of 
Functional Neurosurgery, UCL Institute of Neurology, Queen Square, London, is supported 
by the Parkinson’s Appeal and the Monument Trust. Dr Kefalopoulou is supported by a 
European Union FP-7 grant (TRANSEURO). 
 
We gratefully acknowledge the contribution of the Birmingham, UK Tourette syndrome/team 
in particular Dr Andrea Cavanna, who contributed to the initial trial protocol design, but was 
unable to participate in the trial itself. 
 
 
 
 
 
 
References  
1. Robertson MM, Trimble MR, Lees AJ. The psychopathology of the Gilles de la Tourette 
syndrome. A phenomenological analysis. Br J Psychiatry 1988; 152: 383–90. 
 
2. Leckman JF. Tourette’s syndrome. Lancet 2002; 360: 1577–86. 
 
3. Bloch MH, Leckman JF. Clinical course of Tourette syndrome. J Psychosom Res 2009; 
67: 497–501. 
 
4. Stern JS, Burza S, Robertson MM. Gilles de la Tourette's syndrome and its impact in the 
UK. Postgrad Med J 2005; 81: 12–9. 
 
5. Hariz MI, Robertson MM. Gilles de la Tourette syndrome and deep brain stimulation. Eur J 
Neurosci 2010; 32: 1128–34. 
 
6. Vandewalle V, van der Linden C, Groenewegen HJ, Caemaert J. Stereotactic treatment of 
Gilles de la Tourette syndrome by high frequency stimulation of thalamus. Lancet 1999; 353: 
724. 
 
7. Temel Y, Visser-Vandewalle V. Surgery in Tourette syndrome. Mov Disord 2004; 19: 3–14 
 
8. Servello D, Porta M, Sassi M, Brambilla A, Robertson MM. Deep brain stimulation in 18 
patients with severe Gilles de la Tourette syndrome refractory to treatment: the surgery and 
stimulation. J Neurol Neurosurg Psychiatry 2008; 79: 136–42 
 
9. Maciunas RJ, Maddux BN, Riley DE, Whitney CM, Schoenberg MR, Ogrocki PJ, et al. 
Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in 
adults with Tourette syndrome. J Neurosurg 2007; 107: 1004–14. 
 
10. Ackermans L, Duits A, van der Linden C, Tijssen M, Schruers K, Temel Y, et al. Double-
blind clinical trial of thalamic stimulation in patients with Tourette syndrome. Brain 2011; 134: 
832–44. 
 
11. Foltynie T, Hariz MI. Surgical management of Parkinson's disease. Expert Rev 
Neurother 2010; 10 :903–14. 
 
12. Andrews C, Aviles-Olmos I, Hariz M, Foltynie T. Which patients with dystonia benefit 
from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol 
Neurosurg Psychiatry 2010; 81: 1383–9 
 
13. Welter ML, Mallet L, Houeto JL, Karachi C, Czernecki V, Cornu P, et al. Internal pallidal 
and thalamic stimulation in patients with Tourette syndrome. Arch Neurol 2008; 65: 952–7. 
 
14. Martinez-Fernandez R, Zrinzo L, Aviles-Olmos I, Hariz M, Martinez-Torres I, Joyce E, et 
al. Deep brain stimulation for Gilles de la Tourette syndrome: a case series targeting 
subregions of the globus pallidus internus. Mov Disord 2011; 26: 1922–30 
 
15. Cannon E, Silburn P, Coyne T, O'Maley K, Crawford JD, Sachdev PS. Deep brain 
stimulation of anteromedial globus pallidus interna for severe Tourette's syndrome. Am J 
Psychiatry 2012; 169: 860–6. 
 
16. Sachdev PS, Mohan A, Cannon E, Crawford JD, Silberstein P, Cook R, et al. Deep brain 
stimulation of the antero-medial globus pallidus interna for Tourette syndrome. PLoS One 
2014; 9: e104926. 
 
 
 
17. Foltynie T, Zrinzo L, Martinez-Torres I, Tripoliti E, Petersen E, Holl E, et al. MRI-guided 
STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety. J 
Neurol Neurosurg Psychiatry 2011; 82: 358–63. 
 
18. Holl EM, Petersen EA, Foltynie T, Martinez-Torres I, Limousin P, Hariz MI, et al. 
Improving targeting in image-guided frame-based deep brain stimulation. Neurosurgery 
2010; 67: 437–47. 
 
19. Plaha P, Ben-Shlomo Y, Patel NK, Gill SS. Stimulation of the caudal zona incerta is 
superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. 
Brain 2006; 129: 1732–47. 
 
20. Piedimonte F, Andreani JC, Piedimonte L, Graff P, Bacaro V, Micheli F, Vilela Filho O. 
Behavioral and motor improvement after deep brain stimulation of the globus pallidus 
externus in a case of Tourette's syndrome. Neuromodulation 2013; 16: 55-8. 
 
21. Porta M, Servello D, Zanaboni C, Anasetti F, Menghetti C, Sassi M, et al. Deep brain 
stimulation for treatment of refractory Tourette syndrome: long-term follow-up. Acta 
Neurochir (Wien) 2012; 154: 2029–41. 
  
22. Okun MS, Foote KD, Wu SS, Ward HE, Bowers D, Rodriguez RL, et al. A trial of 
scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep 
brain stimulation paradigms. JAMA Neurol 2013; 70: 85–94. 
 
23. Schrock LE, Mink JW, Woods DW, Porta M, Servello D, Visser-Vandewalle V, et al. 
Tourette syndrome deep brain stimulation: A review and updated recommendations. Mov 
Disord 2014; Dec 5 [Epub ahead of print] 
 
24. Huys D, Bartsch C, Koester P, Lenartz D, Maarouf M, Daumann J, et al. Motor 
improvement and emotional stabilisation in patients with Tourette syndrome after deep brain 
stimulation of the ventral anterior and ventrolateral motor part of the thalamus. Biol 
Psychiatry 2014; Jun 2 [Epub ahead of print] 
 
25. Pepper J, Zrinzo L, Mirza B, Foltynie T, Limousin P, Hariz M. The risk of hardware 
infection in deep brain stimulation surgery is greater at impulse generator replacement than 
at the primary procedure. Stereotact Funct Neurosurg 2013; 91: 56–65. 
 
26. Servello D, Sassi M, Gaeta M, Ricci C, Porta M. Tourette syndrome (TS) bears a higher 
rate of inflammatory complications at the implanted hardware in deep brain stimulation 
(DBS). Acta Neurochir (Wien) 2011; 153: 629–32. 
 
27. Krack P, Hariz MI, Baunez C, Guridi J, Obeso JA. Deep brain stimulation: from 
neurology to psychiatry? Trends Neurosci 2010; 33: 474–84. 
 
28. Kopell BH, Greenberg BD. Anatomy and physiology of the basal ganglia: implications for 
DBS in psychiatry. Neurosci Biobehav Rev 2008; 32: 408–22. 
 
29. Ganos C, Roessner V, Munchau A. The functional anatomy of Gilles de la Tourette 
syndrome. Neurosci Biobehav Rev 2013; 37: 1050–62. 
 
30. Worbe Y, Sgambato-Faure V, Epinat J, Chaigneau M, Tande D, Francois C, et al. 
Towards a primate model of Gilles de la Tourette syndrome: anatomo-behavioural 
correlation of disorders induced by striatal dysfunction. Cortex 2013; 49: 1126–40. 
 
 
 
31. Houeto JL, Karachi C, Mallet L, Pillon B, Yelnik J, Mesnage V, et al. Tourette's syndrome 
and deep brain stimulation. J Neurol Neurosurg Psychiatry 2005; 76: 992–5. 
 
Figure legends 
Figure 1. Randomized double-blind crossover design of the study. 
 
Figure 2. Trial profile. 
 
Figure 3. Axial view from Schaltenbrand atlas to indicate location of active DBS contacts 
during blinded phase (patients a,b,d,e,f,g,h,j,k,l,m,n,o) and open label phase (patients c, i) 
within Left and Right Globus Pallidus. Depth in relation to the midcommissural plane is 
shown on the left. Selected abbreviations: GPi: globus pallidus pars interna; Pl: pars lateralis 
(pars externa) of pallidum; P.m.e: pars medialis externa and P.m.i: pars medialis interna of 
GPi; Ru: red nucleus; Sth: subthalamic nucleus; (Adapted from Schaltenbrand G, Wahren 
W. Atlas for Stereotaxy of the Human Brain, 2nd ed. New York: Thieme; 1977. Plates 53-55. 
Reprinted by permission.)  
 
Table legends 
Table 1. Baseline clinical characteristics of the study population.  M: Male; F: Female. All 
patients had tried at least 3 classes of medication including dopamine blocking agents. 
 
Table 2. Individual results on YGTSS total score in all 15 patients, at baseline, ON/OFF 
blinded, and open-label assessments.  
Yale Global Tic Severity Scale (YGTSS) total score, 0-100. This scale comprises of a total 
tics severity score (-this score provides an evaluation of the number, frequency, intensity, 
complexity and interference of motor and vocal tics and ranges from 0-50) and an 
impairment score (-this score takes into account difficulties in self-esteem, family life, social 
acceptance, or school or job functioning due to tics and ranges from 0-50), with higher 
scores indicating greater severity.  During trial recruitment, for the purposes of inclusion the 
impairment sub-score was transformed to a 0-5 analogue and added to the total tics severity 
score (range 0-55). Positive difference means improvement. *For purposes of maintaining 
confidentiality the patient sequence presented in tables 2 (and supplementary table 5) do not 
correspond to the sequence presented in table 1.   Primary endpoint analysis. § Post hoc 
analysis.  
 
Table 3. Pre-specified secondary outcomes & post hoc analyses 
Yale–Brown Obsessive Compulsive Scale (Y-BOCS) is a clinician-administered scale for the 
evaluation of obsessive compulsive symptoms and consists of 10 sub-items, items 1-5 are 
about obsessive thoughts and 6-10 about compulsions, total scores range from 0-40. The 
Modified Rush Video Rating Scale (MRVRS) scores are based on 5minute tic counts 
considering motor and vocal tic frequency and severity during two 5-minute periods, one 
observed and one unobserved, scores ranging from 0-20 each.  The Gilles de la Tourette 
Syndrome–Quality of Life Scale (GTS-QoL) is a disease-specific patient-reported scale for 
the measurement quality of life in Tourette’s patients: it consists of 27 items covering 
psychological, physical, obsessional, and cognitive aspects of the disorder, score range 0-
108. MOVES is a clinician administered scale, consisting of 20 items evaluating motor and 
vocal tics, obsession and compulsions and associate features with scores ranging from 0-60. 
Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory 
measuring the severity of depression and scores range from 0-63. The State-Trait Anxiety 
Inventory (STAI) consists of 20 questions on a self-report basis measuring the severity of 
anxiety with scores ranging from 20-80. The Neuropsychiatric inventory (NPI) is a 
comprehensive assessment of 12 behavioural disturbances capturing frequency, severity of 
each behaviour and distress caused. The Trail Making test is a neuropsychological test of 
visual attention and task switching, measuring time (s) taken to complete the task. In the 
Paced Auditory Serial Addition test (PASAT), subjects are given a number every 4 seconds 
 
 
and asked to add it to the number before (scores 0-30). For these scales higher scores 
indicate more severe condition. The California Verbal learning test (CVLT) was used to 
measure immediate recall of a list of 16 words over 5 trials. The Recognition memory for 
faces (RMF) measures accuracy of recall of 25 faces. The Verbal Fluency test measures 
how many words can be produced for each of 3 letters for 1 minute per letter. The Letter 
cancellation test (NAB Numbers and letters test) is used to evaluate deficits in attention and 
calculates an efficiency score based on errors and speed (maximum score 200). The Corsi 
block test is a neuropsychological test that assesses visuospatial short term working 
memory (maximum score 16). For these tests, lower scores indicate a more severe 
condition. 
* The comparison between baseline and open label follow up is a post hoc analysis. 
 
 Table 4. Adverse events in all 15 patients during the whole study period.  
* refers to percentage of patients; ¥ refers to percentage of events 
 
Table 5.  Stimulation parameters (supplementary data). *For purposes of maintaining 
confidentiality the patient sequence presented in tables 2 (and supplementary table 5) do not 
correspond to the sequence presented in table 1.  
 
  
 
 
Tables 
 
Table 1. 
 
Patient Se
x 
Age at 
onset 
(years) 
Age at 
surgery 
(years) 
Co-morbidities Medication at 
inclusion 
1 M 11 33 Obsessive compulsive 
disorder, Generalised 
anxiety disorder 
NIL 
2 F 7 55 Tardive dystonia 
History of depression 
Diazepam 10mg  
3 M 8 26 Depression, Generalised 
anxiety disorder, History of 
alcohol/substance misuse 
Fluoxetine 10mg 
4 M 7 24 Generalised anxiety 
disorder, Panic disorder, 
Depression 
NIL 
5 M 5 26 Obsessive compulsive 
behaviour,  history of 
depression 
Fluoxetine 20mg 
6 M 6 38 Obsessive compulsive 
disorder, Depression, 
Generalised anxiety 
disorder, self-injurious 
behaviour 
Venlafaxine 
225mg 
Promethazine 
100mg Diazepam 
15mg  
Zolpidem 10mg 
7 M 7 25 Obsessive compulsive 
behaviour 
NIL 
8 F 12 49 Depression Amitriptyline10mg 
Citalopram 20mg 
Clonidine  500mg  
Zopiclone 11.25mg 
9 M 7 49 Obsessive compulsive 
disorder, Depression 
Fluoxetine 20mg 
10 F 23 34 Obsessive compulsive 
disorder 
Clonazepam 1mg 
11 M 2 29 NIL NIL 
12 M 6 39 Obsessive compulsive 
disorder, Depression, self-
injurious behaviour 
Fluoxetine 40mg 
Haloperidol 2mg 
13 M 6 43 History of obsessive 
compulsive disorder 
Fluoxetine 40mg  
Risperidone 3mg 
14 F 3 25 History of obsessive 
compulsive disorder, 
borderline personality 
disorder, eating disorder,  
self-injurious behaviour, 
psychotic episode  
Clozapine 150mg  
Gabapentin 
3600mg Sertraline 
200mg  
Clonidine  250mg 
Zopiclone 15mg 
Topiramate 200mg 
15 M 7 25 Obsessive compulsive 
disorder, Generalised 
anxiety disorder, 
Depression 
Baclofen 80mg 
Diazepam 10-
30mg 
 
 
 
Table 2.  
 
Patients 
1-15* 
Baseli
ne 
6 
weeks  
post-
op 
RANDO
M-
ISATION 
SEQUE
NCE 
Blinde
d OFF-
STIM 
Blinde
d ON-
STIM 
Open-
label 
ON-
STIM 
Change 
 
Blinded 
OFF-
STIM vs 
Blinded 
ON-
STIM 
(%) 
Change 
 
  
Baseline  
vs  
open-
label  
ON-STIM 
(%) 
a. 80 48 OFF, ON 68 39 33 29 
(42·6%) 
47 
(58·6%) 
b. 99 98 OFF, ON 99 78 42 21 
(21·2%) 
47 
(57·6%) 
c. 93 92  n/a n/a 4 n/a 89 
(95·7%) 
d. 87 74 OFF, ON 85 66 63 19 
(22·4%) 
24 
(27·6%) 
e. 81 81 OFF, ON 81 81 66 0 
(0%) 
15 
(18·5%) 
f. 93 70 ON, OFF 67 59 48 8 
(11·9%) 
45 
(48·4%) 
g. 74 75 ON, OFF 75 77 74 -2 
(-2·7%) 
0 
(0%) 
h. 93 79 OFF, ON 82 63 49 19 
(23·2%) 
44  
(47·3%) 
i. 82 83 ON, OFF n/a n/a 47 n/a 35 
(42·7%) 
j. 80 55 ON, OFF 67 62 62 5 
(7·5%) 
18 
(22·5%) 
k. 96 96 ON, OFF 70 55 46 15 
(21·4%) 
50 
(52·1%) 
l. 71 59 OFF, ON 71 71 59 0 
(0%) 
12 
(16·9%) 
m. 98 97 ON, OFF 94 97 83 -3 
(-3·1%) 
15 
(15·3%) 
n. 99 100 OFF, ON 98 100 51 -2 
(-2·0%) 
48 
(48·5%) 
o. 92 40 ON, OFF 92 40 46 52 
(56·5%) 
46 
(50%) 
Mean  
(SD) 
 
87·9 
(9·2) 
 
76·5  
(19·1) 
 
 80·7  
(12·0) 
 
68·3  
(18·6) 
 
51·5  
(18·5) 
 
12·4 
(15·9) 
95%CI 
(0·1-
24·7) 
p=0.048
 
36.3  
(22.6) 
95%CI 
(23·8- 
48·9) 
p<0.0001
§ 
Mean % 
differen
ce 
(SD)  
 15·3% 
(18·6) 
  
40·1% 
(23·7) 
  
 
 
 
 
 
 
 
 
Table 3. 
Outcome 
measure 
(range) 
Baseline 6 
weeks 
post-
op 
Blinded 
OFF-
STIM 
Blinded 
ON-
STIM 
Open-
label 
ON-
STIM 
Repeated 
measures 
ANOVA 
(F 
statistic) 
P value 
Baseline 
vs open-
label 
Paired T 
test* 
(T 
statistic) 
p value 
 
 
Pre-specified 
Secondary 
outcome 
measures 
Mean 
(SD) 
  
GTS-QoL 
(0-108) 
71·5 
(21·8) 
55·5 
(23·6) 
62·0 
(24·7) 
54·3 
(28·4) 
43·7 
(29·6) 
(3·3) 
0·038 
(4.1) 
0·001 
Y-BOCS  
(0-40) 
13·8  
(10·1) 
12·7 
(9·6) 
14·6 
(10·3) 
12·8 
(10·0) 
10·7 
(9·3) 
(0·02) 
0·979 
(1.8) 
0·090 
BDI 
(0-63) 
25·7  
(12·5) 
19·3 
(12·4) 
20·5 
(14·3) 
21·0 
(13·8) 
14·6 
(12·4) 
(2·6) 
0·127 
(2.6) 
0·025 
STAI 
(20-80) 
56·9  
(14·1) 
52·3 
(13·6) 
55·1 
(15·8) 
56·3 
(15·9) 
47·6 
(16·1) 
(1·2) 
0·352 
(2.1) 
0·057 
NPI total 
(0-144) 
19·7  
(15·8) 
13·2 
(11·1) 
15·4 
(14·8) 
16·8 
(11·9) 
- 
(3·7) 
0·071 
 
NPI distress 
(0-60) 
9·5 
(7·5) 
7·1 
(7·1) 
7·7 
(6·5) 
7·9 
(6·1) 
- 
(2·6) 
0·137 
 
CVLT Trial 1  
(0-16) 
6·6 
(1·1) 
6·5 
(1·4) 
8·6 
(1·9) 
6·9 
(1·6) 
- 
(10·4) 
0·005 
 
CVLT Trial 5 
(0-16) 
12·9 
(1·7) 
12·8 
(2·2) 
13·5 
(1·8) 
13·5 
(3·1) 
- 
(0·7) 
0·522 
 
RMF 
(0-25) 
23·8 
(1·3) 
24·1 
(1·4) 
24·1 
(1·9) 
24·3 
(0·9) 
- 
(0·9) 
0·446 
 
Verbal 
Fluency 
41·5  
(12·1) 
39·9 
(9·3) 
44·7 
(10·7) 
45·6 
(12·7) 
- 
(0·2) 
0·828 
 
Trail Making 
Test –B 
(seconds) 
84·7 
(27·8) 
71·3 
(12·3) 
70·6 
(23·8) 
71·7 
(16·5) 
- 
(3·2) 
0·095 
 
Stroop 
Interference 
(seconds) 
57·3 
(16) 
58·5 
(13·8) 
53·6 
(15·1) 
56·3 
(15·3) 
- 
(1·9) 
0·213 
 
PASAT 
Errors 
(0-30) 
9·3 
(5·8) 
10·3 
(6·8) 
6·5 
(4·0) 
7·6 
(2·3) 
- 
(0·8) 
0·477 
 
Letter 
Cancellation 
test 
(0-200) 
90·5 
(16·2) 
94·5 
(13·9) 
98·1 
(13·7) 
95·4 
(19·0) 
- 
(3·3) 
0·092 
 
Corsi Blocks 
(0-16) 
7·3 
(1·4) 
7·8 
(1·5) 
7·5 
(2·2) 
7·5 
(1·1) 
- 
(0·1) 
0·949 
 
Post-hoc 
Analyses 
Mean 
(SD) 
  
YGTSS 
Motor 
(0-25) 
22·3 
(2·0) 
20·5 
(4·3) 
20·9 
(2·0) 
17·9 
(4·1) 
13·7 
(4·3) 
(9·2) 
0·005 
(6.7) 
<0·0001 
YGTSS 
Vocal  
(0-25) 
19·5 
(3·6) 
17·9 
(4·4) 
19·1 
(3·7) 
16·5 
(4·4) 
12·5 
(5·4) 
(5·2) 
0·026 
(5.2) 
<0·0001 
YGTSS 
Impairment 
(0-50) 
46·0 
(5·1) 
38·0 
(11·5) 
40·8 
(8·6) 
33·9 
(11·9) 
25·3 
(11·9) 
(6·0) 
0·018 
(5.8) 
<0·0001 
MDRVS 
observed 
(0-20) 
15·5 
(3·2) 
14·7 
(3·6) 
14·9 
(3·1) 
12·8 
(3·3) 
10·6 
(3·6) 
(7·7) 
0·010 
(5.4) 
<0·0001 
 
 
  
MDRVS  
unobserved 
(0-20) 
16·9 
(2·3) 
15·4 
(3·4) 
15·4 
(3·1) 
14·0 
(2·8) 
11·6 
(3·7) 
(12·2) 
0·002 
(5.6) 
<0·0001 
MOVES 
(0-60) 
35·0 
(10·1) 
30·2 
(10·1) 
34·9 
(11·4) 
30·8 
(12·3) 
25·9 
(14·9) 
(0·9) 
0·425 
(2.9) 
0·013 
 
 
 
Table 4. 
 
 
 
Adverse Event    
Serious Events Resolved 
Related to surgery or device   
Battery infection necessitated removal 
of system and re-implantation  
2 2 
Related to stimulation   
Deterioration of condition, hypomanic 
behaviour, admission to psychiatric 
ward 
1 1 
Total 3 (20%*) 3 (100%¥) 
Non-serious   
Related to surgery or device   
Prolonged pain around IPG 1 1 
Keloid scar formation 1 0 
Burr hole cap discomfort 1 0 
Connection cable discomfort 1 0 
Upper respiratory tract infection 1 1 
Related to stimulation   
Increased anxiety 2 1 
Insomnia 2 2 
Irritability 3 3 
Tiredness/ lack of energy 2 1 
Headaches 2 1 
Mood deterioration 1 0 
Emotional lability 1 1 
Upper respiratory tract infection 1 1 
Abdominal rush 1 1 
Panic attacks 1 1 
Mild dysarthria  1 0 
Lower limb dyskinesia  1 1 
Total 23 (66·7%*) 15 (60%¥) 
